chr2-47806329-C-G
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBS1_Supporting
The NM_000179.3(MSH6):āc.3772C>Gā(p.Gln1258Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000155 in 1,614,088 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152138Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251214Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135772
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461832Hom.: 0 Cov.: 33 AF XY: 0.0000165 AC XY: 12AN XY: 727210
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152256Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74450
ClinVar
Submissions by phenotype
not specified Uncertain:2
- -
Variant summary: MSH6 c.3772C>G (p.Gln1258Glu) results in a conservative amino acid change located in the C-terminal domain of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4e-05 in 251214 control chromosomes, predominantly at a frequency of 0.00049 within the East Asian subpopulation in the gnomAD database. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3772C>G has been reported in the literature in individuals affected with Lynch Syndrome (Rossi_2017, Soares_2018, Schneider_2018) and familial breast cancer (Wang_2019). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant (after 2014) and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
not provided Uncertain:2
In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast cancer or suspected Lynch syndrome (Ross 2017, Schneider 2018, Kiyozumi 2019, Wang 2019, Shin 2020); This variant is associated with the following publications: (PMID: 28932927, 28874130, 29575718, 30982232, 32019277, 31386297, 17531815, 21120944) -
The MSH6 c.3772C (p.Gln1258Glu) variant has been reported in the published literature in individuals with breast (PMIDs: 30982232 (2019), 32019277 (2020)), colorectal (PMIDs: 28874130 (2017), 28932927 (2018), 29575718 (2018)), pancreatic (PMID: 32980694 (2020)), and bile duct cancer (PMID: 31666926 (2019)). The frequency of this variant in the general population, 0.00049 (9/18392 chromosomes in East Asian subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces glutamine with glutamic acid at codon 1258 of the MSH6 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been observed in individuals affected with Lynch syndrome (PMID: 28874130, 28932927, 29575718, 31386297), pancreatic cancer (PMID: 32980694), and breast or ovarian cancer (PMID: 30982232, 32019277). One individual affected with Lynch syndrome was reported to have an unspecified pathogenic co-variant and lacked phenotypes expected for biallelic constitutional mismatch repair deficiency (PMID: 29575718), while another showed microsatellite stability and presence of mismatch repair proteins by immunohistochemistry (PMID: 31386297). This variant has been identified in 10/251214 chromosomes in the general population by the Genome Aggregation Database (gnomAD) and has been reported in healthy individuals (PMID: 32980694). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.Q1258E variant (also known as c.3772C>G), located in coding exon 8 of the MSH6 gene, results from a C to G substitution at nucleotide position 3772. The glutamine at codon 1258 is replaced by glutamic acid, an amino acid with highly similar properties. This alteration was detected in a Korean individual whose colorectal tumor was microsatellite stable (MSS) and demonstrated normal mismatch repair protein expression on immunohistochemistry (Kiyozumi Y et al. Cancer Med, 2019 Sep;8:5534-5543); however, this alteration was also detected in one family from Brazil with suspected Lynch syndrome (Rossi BM et al. BMC Cancer, 2017 Sep;17:623). This alteration was reported in a Brazilian individual with no features of CMRD who also had MLH1 p.Lys618Glu (Schneider NB et al. Cancer Med, 2018 05;7:2078-2088). This alteration was identified in a cohort of patients diagnosed with biliary tract carcinoma undergoing multigene panel testing for hereditary cancer risk (Terashima T et al. Oncotarget, 2019 Oct;10:5949-5957), as well as in 1/496 Korean patients with clinical features of hereditary breast and ovarian cancer syndrome (HBOC) (Shin HC et al. Cancer Res Treat, 2020 Jul;52:697-713). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Lynch syndrome Uncertain:1
This missense variant replaces glutamine with glutamic acid at codon 1258 of the MSH6 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been observed in individuals affected with Lynch syndrome (PMID: 28874130, 28932927, 29575718, 31386297), pancreatic cancer (PMID: 32980694), and breast or ovarian cancer (PMID: 30982232, 32019277). One individual affected with Lynch syndrome was reported to have an unspecified pathogenic co-variant and lacked phenotypes expected for biallelic constitutional mismatch repair deficiency (PMID: 29575718), while another showed microsatellite stability and presence of mismatch repair proteins by immunohistochemistry (PMID: 31386297). This variant has been identified in 10/251214 chromosomes in the general population by the Genome Aggregation Database (gnomAD) and has been reported in healthy individuals (PMID: 32980694). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Endometrial carcinoma Uncertain:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at